Multi-omics insights into uric acid metabolism in cardiometabolic disease: from genetics to metabolomics
Biomedical Journal · 2026-10 · 49 (5) · 100997
DOI: 10.1016/j.bj.2026.100997 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedical Journal, 2026-10. Verfasst von Nurshad Ali. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, Bangladesh. Electronic address: nali-bmb@su…. Hauptthemen laut MEDLINE: Metabolomics, Uric Acid, Cardiovascular Diseases, Hyperuricemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hyperuricemia, characterized by elevated serum uric acid (SUA) levels, is increasingly recognized as a significant contributor to cardiometabolic diseases including hypertension, type 2 diabetes, chronic kidney disease, metabolic syndrome, and atherosclerotic cardiovascular disease. In the past, uric acid was seen mainly as a byproduct of purine metabolism linked to gout. However, growing evidence suggests that it plays an active role in causing metabolic and vascular dysfunction. Mechanistic studies have shown that higher uric acid levels can induce endothelial dysfunction, oxidative stress, inflammation, insulin resistance, and activation of the renin-angiotensin-aldosterone system, which together can worsen cardiometabolic conditions. Recent advances in high-throughput omics technologies have greatly improved understanding of the molecular mechanisms regulating uric acid metabolism. Genome-wide association studies (GWAS) have identified important urate transporter genes like SLC2A9, ABCG2, and SLC22A12, while epigenomic studies reveal how DNA methylation, histone changes, and non-coding RNAs connect genetic factors to environmental influences. Transcriptomic and single-cell RNA sequencing analyses explain how urate transport and inflammatory signaling are regulated in specific tissues, including the kidneys, liver, adipose, and vascular tissue. In parallel, metabolomic and proteomic studies have linked hyperuricemia to disruptions in purine metabolism, redox balance, lipid remodeling, and inflammatory protein networks. Together, multi-omics approaches that integrate genomics, epigenomics, transcriptomics, proteomics, and metabolomics, along with expression quantitative trait locus (eQTL) mapping, causal modeling, network biology, and AI analysis, now provide powerful tools for biomarker discovery and mechanistic interpretation. This review summarizes current insights into uric acid metabolism from a multi-omics perspective and highlights emerging opportunities for better risk assessment, biomarker discovery, therapeutic targeting, and tailored prevention strategies in cardiometabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, Bangladesh. Electronic address: nali-bmb@sust.edu.
Zitieren
APA
Ali, N. (2026). Multi-omics insights into uric acid metabolism in cardiometabolic disease: from genetics to metabolomics. Biomedical Journal, 49(5), 100997. https://doi.org/10.1016/j.bj.2026.100997
Vancouver
Ali N. Multi-omics insights into uric acid metabolism in cardiometabolic disease: from genetics to metabolomics. Biomedical Journal. 2026;49(5):100997. doi:10.1016/j.bj.2026.100997
BibTeX
@article{Ali2026,
author = {Ali, Nurshad},
title = {Multi-omics insights into uric acid metabolism in cardiometabolic disease: from genetics to metabolomics},
journal = {Biomedical Journal},
year = {2026},
volume = {49},
number = {5},
pages = {100997},
doi = {10.1016/j.bj.2026.100997}
}
EUVIMED